Close Menu

NEW YORK – Infectious disease diagnostic company HelixBind announced Thursday it has received $3 million from the National Institutes of Health to evaluate the company's early detection test for Lyme disease. 

The money is to support clinical studies evaluating the test, which detects DNA from tick-borne bacteria Borrelia burgdorferi directly from the patient's blood. The test has a limit of detection of less than 1 cell per milliliter and can detect the infection at "the earliest timepoint," the company said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.